Literature DB >> 10727301

IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.

R Döpp1, E Schmidt, I Chimanovitch, M Leverkus, E B Bröcker, D Zillikens.   

Abstract

BACKGROUND: Bullous pemphigoid (BP) is an autoimmune blistering disease associated with autoantibodies against the hemidesmosomal glycoprotein BP180. The noncollagenous (NC)16A domain of BP180 has recently been shown to harbor major antigenic sites recognized by BP sera.
OBJECTIVE: The purpose of this study was to characterize the subclass distribution and fine specificities of autoantibodies to BP180 NC16A present in the circulation of patients with BP before, and during the course of, therapy for this disease.
METHODS: Eighteen BP sera were analyzed by immunoblotting and enzyme-linked immunosorbent assay for the presence of IgG1, IgG2, IgG3, IgG4, and IgE reactive with various sites on the BP180 NC16A domain. The sera were collected before treatment was started and at 4- and 8-week time points after initiation of treatment.
RESULTS: We identified IgG4 and IgE as the major immunoglobulins that preferentially react with two distinct epitopes (MCW-1 and MCW-2) within BP180 NC16A. Levels of these autoantibodies correlated with disease activity in BP. During the course of disease, no change was observed with regard to the immunoglobulin subclass predominantly reacting with BP180 NC16A or the specific epitopes within this domain.
CONCLUSION: Our data demonstrate that remission of BP is paralleled by a decrease of serum levels of IgE and the different IgG subclasses reactive with BP180 NC16A.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10727301

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  43 in total

Review 1.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  The diagnosis and treatment of autoimmune blistering skin diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Dtsch Arztebl Int       Date:  2011-06-10       Impact factor: 5.594

3.  Membranous glomerulonephropathy in a patient with bullous pemphigoid.

Authors:  Misa Ikeda; Hirokazu Honda; Naoto Kobayashi; Shoko Onuma; Kei Matsumoto; Tadao Akizawa; Yutaka Yamaguchi; Takanori Shibata
Journal:  CEN Case Rep       Date:  2016-11-04

Review 4.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

5.  Enrichment of total serum IgG4 in patients with pemphigus.

Authors:  T Funakoshi; L Lunardon; C T Ellebrecht; A R Nagler; C E O'Leary; A S Payne
Journal:  Br J Dermatol       Date:  2012-09-27       Impact factor: 9.302

Review 6.  Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.

Authors:  K A N Messingham; H M Holahan; J A Fairley
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

7.  Eosinophil localization to the basement membrane zone is autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid.

Authors:  Kelly N Messingham; Jeffrey W Wang; Heather M Holahan; Rupasree Srikantha; Samantha C Aust; Janet A Fairley
Journal:  Exp Dermatol       Date:  2015-11-23       Impact factor: 3.960

Review 8.  Clinical and serological responses following plasmapheresis in bullous pemphigoid: two case reports and a review of the literature.

Authors:  Brian Chang; Ashok Tholpady; Richard S P Huang; Elena Nedelcu; Yu Bai
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

9.  Diagnosis and clinical severity markers of bullous pemphigoid.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  F1000 Med Rep       Date:  2009-02-24

10.  Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model.

Authors:  Zhi Liu; Wen Sui; Minglang Zhao; Zhuowei Li; Ning Li; Randy Thresher; George J Giudice; Janet A Fairley; Cassian Sitaru; Detlef Zillikens; Gang Ning; M Peter Marinkovich; Luis A Diaz
Journal:  J Autoimmun       Date:  2008-10-14       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.